Hebei Aipu Pharmaceutical Co., Ltd.

Primary objective: To compare the pharmacokinetic parameters of the test preparation and the reference preparation, using the febuxostat tablets (specification: 40 mg) licensed by Hebei Aipu Pharmaceutical Co., Ltd. as the test preparation T and the febuxostat tablets (specification: 40 mg, trade name: Feburic®) produced by Teijin Pharma Limited as the reference preparation R, and to evaluate the bioequivalence of the two preparations in the human body under the fed state. Secondary objective: To observe the safety of the test preparation, febuxostat tablets T, and the reference preparation, febuxostat tablets R (trade name: Feburic®) in healthy subjects.

Primary objective: To compare the pharmacokinetic parameters of the test preparation and the reference preparation, and to evaluate the bioequivalence of the two preparations in the fasting state, using the febuxostat tablets (specification: 40 mg) licensed by Hebei Aipu Pharmaceutical Co., Ltd. as the test preparation T and the febuxostat tablets (specification: 40 mg, trade name: Feburic®) produced by Teijin Pharma Limited as the reference preparation R. Secondary objective: To observe the safety of the test preparation, febuxostat tablets T, and the reference preparation, febuxostat tablets R (trade name: Feburic®) in healthy subjects.

To study the pharmacokinetic characteristics of a single oral administration of felodipine sustained-release tablets (test preparation T, specification: 5 mg) produced by Hebei Aipu Pharmaceutical Co., Ltd. under fasting and postprandial conditions in healthy subjects and a single oral administration of felodipine sustained-release tablets (reference preparation R, trade name: Plendil®, specification: 5 mg) certified by AstraZeneca Pharmaceuticals Co., Ltd. under the same conditions, evaluate the bioequivalence and safety of the two preparations, and provide a basis for the registration application of the test preparation.